Peter Farina, Ph.D., is passionate about research and development in the fields of chemistry and biology. Peter joined Canaan in 2008 to identify and evaluate strategic investment opportunities by applying his background in research and drug development.
Previous to joining Canaan, Peter served as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, Inc., where he was responsible for the North American development of drugs in the therapeutic areas of immunology/inflammation, virology and cardiovascular disease. Peter also served as vice president of research, director of inflammatory diseases and director of biochemistry during his 28 year career with the company. Prior to joining Boehringer Ingelheim, Peter worked on the development of immunodiagnostics for the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation.
Some of Peter’s most notable accomplishments include the successful development and registration of the reverse transcriptase inhibitor, Viramune® (nevirapine), HIV protease inhibitor, Aptivus®, and Atrovent HFA® for COPD and emphysema. He has also authored more than fifty publications and patents.
Peter currently serves as the co-chair and board member of Connecticut United for Research Excellence (CURE); the advisory board of the University of Connecticut School of Pharmacy; advises several biotech companies with a China focus and was founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases. He holds a Ph.D. in organic chemistry from SUNY Buffalo and conducted postdoctoral work in bioorganic chemistry at Pennsylvania State University.